ClinicalTrials.gov
public full text
Public Domain
Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma
Primary: Evaluate safety, feasibility, persistence, and anti-tumor effect of infused haploidentical donor-derived natural killer (NK) cells and low-dose interleukin-2 (IL-2). Secondary: * Quantification of cytokine levels; * Assessment of NK cell immunophenotype and function.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Safety and Efficacy of Autologous Natural Killer Cell Therapy (CHANK-101) in Patients With Recurrent Glioblastoma#1140973
- Checkpoint inhibitor effectiveness after corticosteroids and second-line immunosuppressants for immune-related adverse events in non-small-cell lung cancer#374506
- Safety of Expanded Haploidentical Natural Killer Cells for Leukemia#28303
- Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies#172284
- Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma#226241
Record · ID 1125566
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive